Mersana Therapeutics, Inc. (MRSN)
Market Cap | 43.50M |
Revenue (ttm) | 34.01M |
Net Income (ttm) | -74.01M |
Shares Out | 124.63M |
EPS (ttm) | -0.60 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 2,236,806 |
Open | 0.3680 |
Previous Close | 0.3659 |
Day's Range | 0.3412 - 0.3730 |
52-Week Range | 0.2589 - 2.8300 |
Beta | 1.30 |
Analysts | Strong Buy |
Price Target | 5.75 (+1,547.56%) |
Earnings Date | May 15, 2025 |
About MRSN
Mersana Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops antibody-drug conjugates (ADC) for cancer patients with unmet needs. The company develops Emi-Le (XMT-1660), a B7-H4-targeting Dolasynthen ADC candidate, which is in Phase 1 clinical trial; and XMT-2056, an Immunosynthen ADC targeting a novel human epidermal growth factor receptor 2 that is in Phase 1 clinical trial. Its preclinical products portfolio includes XMT-2068 and XMT-2175. It has strategic research and development collaborations with Janssen Biotech, Inc.... [Read more]
Financial Performance
In 2024, Mersana Therapeutics's revenue was $40.50 million, an increase of 9.88% compared to the previous year's $36.86 million. Losses were -$69.19 million, -59.69% less than in 2023.
Financial StatementsAnalyst Forecast
According to 5 analysts, the average rating for MRSN stock is "Strong Buy." The 12-month stock price forecast is $5.75, which is an increase of 1,547.56% from the latest price.
News

Mersana Therapeutics to Present at Upcoming Investor Conferences
CAMBRIDGE, Mass., May 20, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on the development of antibody-drug conjugates (ADCs) t...

Mersana Therapeutics, Inc. (MRSN) Q1 2025 Earnings Call Transcript
Mersana Therapeutics, Inc. (NASDAQ:MRSN) Q1 2025 Earnings Conference Call May 15, 2025 8:00 AM ET Company Participants Jason Fredette - Senior Vice President, Investor Relations & Corporate Communica...

CORRECTION - Mersana Therapeutics Provides Business Update and Announces First Quarter 2025 Financial Results
In a release issued under the same headline earlier today by Mersana Therapeutics, Inc. (NASDAQ: MRSN), please note that there was a transcription error in the last cell of the first table. The Median...

Mersana Therapeutics Provides Business Update and Announces First Quarter 2025 Financial Results
CAMBRIDGE, Mass., May 15, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on developing a pipeline of antibody-drug conjugates (A...

Mersana Therapeutics Announces Strategic Restructuring and Reprioritization Plan Focused on Advancing Emi-Le in Triple-Negative Breast Cancer
CAMBRIDGE, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on developing a pipeline of antibody-drug conjugates (A...

Mersana Therapeutics Announces Upcoming Emi-Le Oral and Poster Presentations at ASCO 2025 Annual Meeting
CAMBRIDGE, Mass., April 23, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-...

Mersana Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., April 04, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-d...

Mersana Therapeutics Announces Upcoming Oral Presentation of Emi-Le Clinical Data at European Society for Medical Oncology (ESMO) Breast Cancer 2025 Annual Congress
CAMBRIDGE, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-...

Mersana Therapeutics, Inc. (MRSN) Q4 2024 Earnings Call Transcript
Mersana Therapeutics, Inc. (MRSN) Q4 2024 Earnings Call Transcript

Mersana Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2024 Financial Results
CAMBRIDGE, Mass., March 03, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-...

Mersana Therapeutics to Host Fourth Quarter and Year End 2024 Conference Call on March 3, 2025
CAMBRIDGE, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-d...

Mersana Therapeutics to Participate in the Guggenheim SMID Cap Biotech Conference
CAMBRIDGE, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-d...

Why Is Cancer-Focused Mersana Therapeutics Stock Trading Lower On Friday?
On Friday, Mersana Therapeutics Inc. MRSN released initial data from the Phase 1 dose escalation and backfill cohorts for emiltatug ledadotin.

Mersana Therapeutics Announces Additional FDA Fast Track Designation Granted to Emiltatug Ledadotin (XMT-1660)
Conference call to discuss positive initial Phase 1 clinical data today at 8:30 a.m. ET Conference call to discuss positive initial Phase 1 clinical data today at 8:30 a.m. ET

Mersana Therapeutics Announces Positive Initial Clinical Data from Phase 1 Clinical Trial of Emiltatug Ledadotin (XMT-1660); Initiation of Expansion in Triple Negative Breast Cancer
- Emiltatug ledadotin observed to be generally well tolerated with differentiated safety and tolerability profile - Promising clinical activity observed in patients with triple-negative breast cancer ...

Mersana Therapeutics: We're About To Find Out If ADC Platform Is More Tolerable
Mersana Therapeutics is developing novel antibody-drug conjugates targeting a heretofore untapped immune checkpoint, as well as HER2 from another angle. The company has an operational runway of 6-7 qu...

Mersana Therapeutics, Inc. (MRSN) Q3 2024 Earnings Call Transcript
Mersana Therapeutics, Inc. (NASDAQ:MRSN) Q3 2024 Earnings Conference Call November 13, 2024 8:00 AM ET Company Participants Jason Fredette - SVP, IR Martin Huber - President & CEO Mohan Bala - SVP, C...

Mersana Therapeutics Provides Business Update and Announces Third Quarter 2024 Financial Results
CAMBRIDGE, Mass., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-d...

Mersana Therapeutics to Host Third Quarter 2024 Conference Call on November 13, 2024
CAMBRIDGE, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-d...

Mersana Therapeutics, Inc. (MRSN) Q2 2024 Earnings Call Transcript
Mersana Therapeutics, Inc. (NASDAQ:MRSN) Q2 2024 Earnings Conference Call August 13, 2024 8:00 AM ET Company Participants Martin Huber - President & CEO Brian DeSchuytner - CFO & COO Jason Fredette -...

Mersana Therapeutics Provides Business Update and Announces Second Quarter 2024 Financial Results
CAMBRIDGE, Mass., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-d...

Mersana Therapeutics to Host Second Quarter 2024 Conference Call on August 13, 2024
CAMBRIDGE, Mass., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-d...

Mersana Therapeutics, Inc. (MRSN) Q1 2024 Earnings Call Transcript
Mersana Therapeutics, Inc. (NASDAQ:MRSN) Q1 2024 Earnings Conference Call May 9, 2024 8:00 AM ET Company Participants Jason Fredette - Senior Vice President, Investor Relations & Corporate Communicat...

Mersana Therapeutics Provides Business Update and Announces First Quarter 2024 Financial Results
CAMBRIDGE, Mass., May 09, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-dr...

Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., May 03, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-dru...